Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy

Keyphrases

• Anti-PD-1 Antibody 50%
• Anticancer Therapeutics 50%
• Exomics 100%
• Immune Checkpoint 100%
• Immunogenic 100%
• Melanoma 50%
• Mutational Heterogeneity 50%
• Mutational Load 100%
• Non-small Cell Lung Cancer (NSCLC) 50%
• Patient with Tumor 50%
• Response Rate 50%
• Somatic mutation 50%
• Targeted Therapy 50%
• Tumor 50%

Biochemistry, Genetics and Molecular Biology

• Anticancer 50%
• Immune Checkpoints 100%
• Mutational Load 100%
• PD-L1 50%
• Somatic Mutation 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 50%
• Neoplasm 100%
• Non Small Cell Lung Cancer 50%